AI agents autonomously process payments, FX, payroll, and reconciliation — capabilities out of reach for most traditional banks Brighty, the European crypto-nativeAI agents autonomously process payments, FX, payroll, and reconciliation — capabilities out of reach for most traditional banks Brighty, the European crypto-native

Brighty Launches Banking AI Agents for Corporate Clients

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

AI agents autonomously process payments, FX, payroll, and reconciliation — capabilities out of reach for most traditional banks

Brighty, the European crypto-native digital finance platform, announces the launch of its Banking API for AI Agents. It’s a developer-ready infrastructure that empowers AI agents to autonomously execute real business banking operations: checking balances, sending payments, converting currencies, managing payroll, and reconciling transactions.

Even digital finance is still manual: most traditional banks remain locked behind legacy infrastructure and manual workflows. For businesses processing hundreds of invoices a month, the status quo is expensive and error-prone entailing a significant drain in staff time and accounting costs.

Brighty’s AI Agents are built for tech-savvy businesses, freelancers, and corporate clients of all sizes. For freelancers juggling clients, invoices, and taxes on their own, and for growing businesses drowning in financial admin — Brighty replaces the chaos with automation, giving them back time and visibility over their money.

Read More on Fintech : Global Fintech Interview with Kristin Kanders, Head of Marketing & Engagement, Plynk App

What AI Agents Can Do with Brighty

Brighty is positioning itself at the frontier of a new category in digital finance: agentic banking. Brighty’s AI agent can read an incoming invoice, determine the correct currency conversion at the live rate, request approval from the relevant stakeholder, and release the payment — all without human intervention. What used to take hours of back-and-forth now happens in seconds.

The API provides programmatic access to a full suite of business banking functions:

  • Real-Time Balance Queries: Query live balances across all accounts and currencies instantly — no screen scraping, no delays.
  • SEPA & SWIFT Payments: Initiate international transfers programmatically with full audit trails and compliance logging.
  • Currency Exchange: Convert between currencies at competitive rates with a single API call — no bridging, no friction.
  • Payroll Automation: Schedule and execute salary payments to employees across multiple countries without manual input.
  • Transaction History & Reconciliation: Access complete transaction records for automated bookkeeping and financial reporting.
  • Account & Permission Management: Configure account settings, access controls, and security rules via API.
  • Issuance and management of bank cards.

Even though Brighty is a crypto-native digital finance platform, AI Agents work beyond crypto and Web3. Brighty is purpose-built for B2B companies — traditional businesses that want to eliminate manual financial operations, reduce accounting overhead, and move at the speed of software.

“We built Brighty on a simple conviction: financial infrastructure should be transparent, programmable, and accessible. With this API, we’re extending that principle to the age of intelligent agents — giving businesses a way to automate financial operations that would otherwise require a team of accountants,” – said Nick Denisenko, Brighty’s Co-Founder and CTO

Catch more Fintech Insights : When DeFi Protocols Become Self-Evolving Organisms

[To share your insights with us, please write to psen@itechseries.com ]

The post Brighty Launches Banking AI Agents for Corporate Clients appeared first on GlobalFinTechSeries.

Market Opportunity
READY Logo
READY Price(READY)
$0.011799
$0.011799$0.011799
+0.77%
USD
READY (READY) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09